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By way of introduction I want to explain that the Rural Advancement Foun-dation International (RAFI) is a private, nonprofit organization that works 
on the interrelated issues of agricultural biodiversity and biotechnology. We 
are an international research and advocacy organization with offices in North 
Carolina, USA and in Ottawa, Canada. Since 1986, my own work has focused 
on the social and economic impacts of emerging biotechnologies, particularly 
as they affect poor farmers and rural communities—especially in the develop-
ing world.
I come here today as an activist and as a critic of biotechnology. But I want 
to stress that I am not against biotechnology or genetic engineering. I think it is 
impossible to assign labels such as “good” or “bad” to a new technology. The 
more fundamental issue is who will control these technologies and who will 
benefit from them.
I cannot think of a more appropriate or important theme than Biotechnol-
ogy and the Public Good for this sixth annual meeting of NABC. It seems to 
me that the format of the workshops scheduled today and tomorrow will al-
low for an interesting discussion of many topics—whether it be under the 
title of structure of agriculture, global interdependence or environmental 
stewardship. Today, I would like to make some brief comments on each of 
these three general topics.
GLOBAL INTERDEPENDENCE
The theme of global interdependence is especially relevant to the topic of bio-
technology and the public good. It is virtually impossible to talk about bio-
technology without looking at the global dimensions and without an appre-
ciation for the interdependence of all nations. One of the common denomina-
tors, of course, is our genetic interdependence. Access to biological resources 
is the lifeblood of agricultural biotechnology. The genes from plants, animals 
and microorganisms of the developing world, in particular, are the “strategic 
raw materials” for the development of new food, pharmaceutical and indus-
trial products. But these genes are seldom “raw materials” in the traditional 
sense because they have been selected, nurtured and improved by untold num-
bers of farmers and indigenous peoples over thousands of years.
All major food crops, the staple crops grown and consumed by the vast 
majority of the world’s population, have their origins and centers of diversity 
in the tropics and subtropics of Asia, Africa and Latin America. Over the past 
12,000 years, Third World farmers selected and domesticated all major food 
crops on which humankind survives today. Fresh infusions of exotic germ- 
plasm are vital for the ongoing maintenance and improvement of agriculture.
Whether they are used in traditional farming systems, conventional 
breeding or modern biotechnology, genetic resources are a global asset of in-
calculable value—now and in the future. As genetic diversity erodes, our ca-
pacity to maintain and enhance agricultural productivity decreases along 
with the ability to respond to ever changing needs and conditions. If we are to 
adapt food production systems to rapidly changing climatic conditions in the 
next century, plant and animal genetic resources will offer the single most critical 
resource for doing so. Biological resources are the key to increasing food secu-
rity and environmental stability, and to improving the human condition.
But I want to stress that the knowledge of farmers and indigenous peoples 
and their role in conserving and developing biodiversity is not ancient history. 
Today, for example, the Ifugao of the Philippine island of Luzon can name 
more than 200 varieties of sweet potato. Jivaro farmers in one Amazonian 
community grow over 100 varieties of manioc. In one Liberian village, Kpelle 
women maintain over 112 varieties of upland rice.
These plant genetic resources reflect the ingenuity, inventiveness and so-
phistication of what we call “informal innovation systems.” There is increas-
ing recognition worldwide that the indigenous knowledge of thousands of 
human cultures is of utmost importance in understanding, utilizing and con-
serving biological diversity for agriculture and sustainable development. The 
subject of biodiversity assumes utmost urgency today because we are losing 
biological resources at an unprecedented rate. A great deal of progress has 
been made in bringing the issue of biodiversity to the global policy arena. In 
late 1993, the Convention on Biological Diversity gave us the first legally- 
binding framework for conservation and sustainable use of biodiversity.
Life  Patenting
Unfortunately, international cooperation to conserve biodiversity and to en-
sure its equitable and sustainable use is jeopardized by the efforts of some in-
dustrialized countries to obtain exclusive monopoly control over genes, plants, 
animals and other living organisms—including human genetic material. With 
the advent of genetic engineering, the biotechnology industry has successfully 
promoted the extension of industrial patenting regimes to all biological prod-
ucts and processes. It has happened in less than 15 years. Many of you are fa-
miliar with the landmark decisions, but let me review them quickly:
—In 1980, the U.S. Supreme Court ruled in the groundbreaking case 
of Diamond vs. Chakrabarty that genetically engineered microorganisms are 
patentable.
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—In 1985, the U.S. Patent Office ruled that plants could be patented un-
der industrial patent laws.
—In 1987, the U.S. Patent Office ruled that genetically engineered ani-
mals are also patentable.
As a result of these decisions, virtually all living organisms in the U.S.—in-
cluding human genetic material—became patentable subject matter just like 
toasters or light bulbs. Genes, plants, animals and microorganisms—whether 
simply discovered in nature or manipulated by genetic engineers—could be 
rendered the intellectual property of private interests.
The biotechnology industry is lobbying vigorously, and quite successfully, 
to see minimum standards of intellectual property enforced worldwide. The 
European Parliament is currently debating the “Directive on the Legal Protec-
tion of Biotechnological Inventions” which proposes to extend life patenting 
in Europe. The recently concluded General Agreements on Tariffs and Trade 
and Trade-Related Aspects of Intellectual Property Rights (GATT-TRIPs) 
agreement will obligate signatory states to adopt intellectual property laws 
covering both microbial materials and plant varieties. This means that many 
developing nations will be forced to adopt plant intellectual property rights 
under the threat of trade sanctions. In many cases, these laws may be entirely 
inappropriate for some nations’ needs and level of development.
Proponents of patenting argue that it stimulates innovation by rewarding 
patent holders and enables companies to recoup their research investment. 
But for farmers and consumers of the developing world, in particular, this 
means having to pay royalties on products which are based on their own bio-
logical resources and knowledge. Let me give three brief examples of what we 
call “Biopiracy.”
The first example is the case of thaumatin, the super-sweet protein de-
rived from a West African plant. Genetic engineers from Lucky Biotech Cor-
poration and the University of California recently received U.S. and world 
patents for any plants that are genetically engineered to express super-sweet 
natural proteins derived from thaumatin.1 The thaumatin plant protein is the 
sweetest substance known to humankind—scientists say it is 100,000 times 
sweeter than sugar. (For background on thaumatin, see Shand 1987a.) It 
grows in the humid tropical forests of West Africa where local people have 
used it for centuries as a sweetener and flavor enhancer. Imagine the potential 
commercial market for a low-calorie, natural sweetener that can be inserted 
into the genetic makeup of any fruit or vegetable! (In the U.S. alone, the mar-
ket for low-calorie sweeteners is $900 million per annum, but West African 
people will have rights to none of it.)
1 International Patent, Publication Number WO 92/01790, dated February 6, 1992 
and U.S. Patent Number 5,234,834.
The second example is the U.S. patent on genetically engineered or trans-
genic cotton.2 (For a complete analysis, see Shand 1993a.) Even biotechnology 
industry representatives were shocked in late 1992 when Agracetus, Inc., a bio-
technology subsidiary of W.R. Grace Corporation, received a patent for all ge-
netically engineered cotton varieties. The first-ever “species patent” gives this 
company the right to decide when and if it chooses to license its technology— 
for how much and under what conditions—until the year 2008. In other 
words, transgenic cotton varieties cannot enter the commercial marketplace 
without payment of royalties to Agracetus. But the impact of this patent is not 
limited to the U.S. Agracetus applied for similar patents in India, China, Brazil 
and Europe, hoping to gain monopoly control over transgenic cotton in areas 
accounting for 60 percent of the world’s cotton production. Cotton was first 
domesticated and improved by farmers in Central and South America. The 
notion that Agracetus “invented” transgenic cotton is offensive and unjust. 
Modern plant breeders and genetic engineers are literally building on the ac-
cumulated success of generations of anonymous farmers. Under the indus-
trial patent system, however, it will be illegal for farmers to save seed from 
transgenic cotton plants without payment of royalties. In addition, utility 
(industrial) patents do not automatically give permission to researchers to 
use protected plant varieties for research purposes or to develop new com-
mercial varieties.
The patenting of a major industrial crop is disturbing enough, but in 
March 1994, the same company, W.R. Grace Corporation, received a Euro-
pean patent on all transgenic soybean.3 (For further details, see Mooney and 
Shand 1994.) RAFI is officially challenging this patent on a major food crop, 
for we view the patent as a threat to world food security. Geoffrey Hawtin, 
Director-General of the International Plant Genetic Resources Institute 
based in Rome, refers to the species-wide patents claimed by Agracetus as 
“economic highjacking.” He states:
The granting of patents covering all genetically engineered 
varieties of a species, irrespective of the genes concerned or 
how they were transferred, puts in the hands of a single in-
ventor the possibility to control what we grow on our farms 
and in our gardens. At a stroke of a pen the research of countless 
farmers and scientists has potentially been negated in a single, 
legal act of economic high jack.4
2 U.S. Patent Number 5,159,135, dated October 27, 1992. Title: Genetic Engineer-
ing of Cotton Plant and Lines.
3 European Patent Office Publicaton Number 0 301 749 Bl, dated March 2, 1994.
4 Quoted in RAFI Press release, F o o d  P a te n t  C h a l le n g e d ,  dated March 30, 1994.
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Patenting  the  Human  Cell  Lines  of  Indigenous  Peoples  
The third and perhaps most disturbing example of biopiracy involves patent 
applications by the U.S. government on the human cell lines of indigenous 
peoples. A year ago, RAFI discovered that the U.S. government had applied for 
U.S. and international patents on the human cell line of a 26-year old Guaymi 
Indian woman from Panama (Shand 1994). A blood sample was taken from 
this woman by a National Institutes of Health (NIH) researcher, who then es-
tablished a cell line—this refers to cells that are capable of sustaining continu-
ous, long-term growth in cultures, i.e., they can live indefinitely under artifi-
cial conditions. The sample was of interest because some Guaymi people carry 
a unique virus, and its antibodies could prove useful in AIDS and leukemia re-
search. The scientist who took the DNA sample from the Guaymi woman fol-
lowed the standard regulations for what is known as “oral informed consent.” 
But informed consent does not require that you tell the research subject that 
you intend to patent genetic material derived from their DNA, or that someone 
stands to profit if a commercial product should someday be developed from 
the patented cell line.
Representatives from the Guaymi Congress in Panama were shocked to 
learn that the U.S. government could apply for patents on the human genetic 
material, let alone the cell line of a foreign national. The Guaymi Indians do 
not object to medical research or to making contributions that will improve 
the human condition, but they were morally outraged that the U.S. govern-
ment would seek monopoly control over human cell lines and potentially profit 
from the genes of poor people. Isidro Acosta, President of the Guaymi Gen-
eral Congress, made this statement at a press conference in Geneva last October:
I never imagined people would patent plants and animals. It 
is fundamentally immoral, contrary to the Guaymi view of 
nature, and our place in it. To patent human material...to take 
human DNA and patent its products...that violates the integ-
rity of life itself, and our deepest sense of morality.5
As a result of protests by the Guaymi Congress, other indigenous peoples’ or-
ganizations, nongovernment organizations (NGOs) and the European Parlia-
ment, the U.S. government silently withdrew its patent claim late last year.6 
But the issue is far from being resolved. In January, 1994, two more patent ap-
plications, again in the name of the U.S. government, were pending in Europe.
5 Translated from Spanish. Quoted in RAFI press release I n d ig e n o u s  P e o p le  P ro te s t
U .S .  S e c re ta r y  o f  C o m m e r c e  P a te n t  C la im  o n  G u a y m i  I n d ia n  C e l l  L in e ,  dated Octo-
ber 26, 1993.
6 Express Abandonment Pursuant to 37 C.F.R. Sec. 1.138, for Human T Lymppho- 
tropic Virus Type 2, from Guaymi Indians in Panama. Letter dated November 1, 
1993 from the Office of Technology Transfer, NIH to the Commissioner of Pat-
ents and Trademarks. Letter submitted by Susan S. Rucker, Attorney.
This time the cell lines come from citizens of the Solomon Islands and Papua 
New Guinea.7 The cell lines are now on deposit at the American Type Culture 
Collection in Washington, DC. But since patent claims are still pending, access 
to these materials is restricted—even to the governments of Papua New Guinea 
and the Solomon Islands.
Private ownership of human biological materials raises many profound 
social, ethical and political issues. The patenting of human cell lines of indig-
enous peoples is clearly a violation of fundamental human rights—some have 
dubbed it a new form of “bio-colonialism.” If these cell lines, or products de-
rived from them, should someday result in commercial products, U.S. courts 
have ruled that the people from whom the genetic material is taken do not have 
rights of ownership over their own cells after they have been removed from 
their bodies8 (see Annas 1993). According to corporate interpretations of the 
Biodiversity Convention, signatory states are obliged to recognize the owner-
ship of genetic materials by countries or companies, but there is no mechanism 
to compensate the individuals or communities from whom the DNA samples 
were taken.
Well, some of you may be wondering what patenting of human genetic 
material has to do with agriculture. 1 mention this case because it clearly has 
a great deal to do with biotechnology and the issue of life patenting, and it 
clearly relates to the public good. The point I want to make is that there is 
enormous controversy and debate over the ownership of genetic resources. 
We do not hear as much about it here in the U.S., but it is an extremely hot 
topic in the rest of the world. And it is a subject we cannot ignore (Khor 1993). 
The ultimate danger is that the exchange of genetic material and information 
which is so vital for food security will be severely constricted, undermining 
efforts to conserve biodiversity and guarantee access to it. Under this sce-
nario, everyone loses.
I will return to the issue of intellectual property rights, but I want to com-
ment briefly on structural changes in agricultural production and trade, par-
ticularly in the developing world.
BIOTECHNOLOGY-STRUCTURAL CHANGES
IN AG RI CULT URAL PRO DUCT I ON AND TRADE
There is little doubt that in the near future biotechnologies will profoundly
shape our economic and social structures and our natural environment.
In agriculture, biotechnology will change not only where our food is pro-
duced, but how it is produced and by whom. Although commercial biotech-
7 WO93/03759 and WO/92/15325-A. Information on these patent applications 
came from Miges Baumann, SWISS AID, a development NGO based in Bern, 
Switzerland, dated January 14, 1994.
8 Moore vs. Regents of the University of California, 793 P2d 479, 271 C a l .  R p t r .  
146 (1990).
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nologies are being developed primarily by food, agrochemical and pharma-
ceutical corporations in the industrialized world, farmers and consumers of 
the developing world will be profoundly affected. Early in the next century 
we will see dramatic changes in global agricultural production and trade— 
with many negative implications for the Third World.
One very real threat is the transfer of production. The ability to produce 
high-value tropical products in the laboratory will ultimately transfer produc-
tion out of farmers’ fields into industrial bioreactors. This could mean massive 
displacement of agricultural workers and disruption of Third World economies.
Vanilla
One classic example is the case of vanilla. In California, a biotechnology com-
pany called Escagenetics is now producing natural vanilla in the laboratory us-
ing a cell culture technique. (For details see Shand 1991.) Instead of cultivat-
ing the vanilla orchid which produces the vanilla bean, this company is grow-
ing cells from the vanilla plant and getting those cells to secrete the natural va-
nilla flavor. No need for soil, sunlight or farmers.
Natural vanilla flavor is, traditionally, an expensive flavoring that can 
only be grown commercially in a few developing countries. Three-quarters 
of the world’s vanilla bean production comes from the island of Madagascar, 
the Comoros and other small islands off the East Coast of Africa where about 
100,000 small farmers are engaged in production of this high-value crop.
It is no exaggeration to say that, i/commercially successful, biosynthetic 
vanilla has the potential to displace vanilla bean exports on a massive scale. 
The last report that I am aware of is that a division of the Unilever Corpora-
tion, Quest International, had entered into an agreement with Escagenetics to 
determine the potential for scaling up the production of biosynthetic vanilla.
Of course, I am not suggesting that these islands should continue to be de-
pendent on export crops like vanilla. But it takes time to diversify economical-
ly and it takes a great deal of planning. Remember, too, that the germplasm 
that makes possible the biosynthetic production of vanilla in the laboratory 
originated in the developing world.
I want to stress that vanilla is just the tip of the iceberg; it represents only 
one of thousands of plant-derived substances and primary export commodi-
ties which may be future targets of biotechnology. Other tropical products 
like coffee, cacao, pyrethrum and rubber are among the commodities now be-
ing targeted.
Biotechnology will also make it possible to substitute one raw material 
for another in modern food processing; the food industry calls this “multiple 
sourcing.” The potential is especially dramatic in genetic modification of oils 
and fats. The industry’s goal is to reduce reliance on high-priced, imported 
oils. Several companies are pursuing the goal of converting cheap oils such as 
palm or soybean into high-quality cocoa butter (Shand 1987b). One California-
based company, Genencor Company, has patented a process to convert palm 
oil into expensive cocoa butter. Fuji Oil Co. of Japan has a patented process to 
develop cocoa butter substitutes from olive, safflower and palm oil. This is 
good news for food processors, and perhaps for consumers as well, but ex-
traordinarily bad news for Third World cacao producers whose annual cocoa 
butter exports are valued at approximately $540 million.
These examples offer a glimpse of some long-term structural change in 
global food and agricultural systems with unintended, though very negative, 
consequences for many developing countries. New, natural substitutes as well 
as novel production processes will alter, reduce or eliminate the need for tradi-
tional cultivation of major food and industrial crops. At stake are not only for-
eign exchange earnings but the livelihoods of literally millions of agricultural 
workers who currently produce these products.
These examples are particularly important in light of the fact that the bio-
technology industry so readily promises that genetic engineering will solve 
problems of hunger in the developing world. And, it is usually the promise of 
technology transfer that is so often mentioned as the reward for developing na-
tions who make available their biological resources. Despite what other pre-
senters indicated, I do not believe that commercial biotechnology is about 
feeding hungry people.
While new biotechnologies do have potential to address food and agri-
cultural problems in the developing world, it is critically important to look at 
the social and economic as well as ecological risks associated with the intro-
duction of these new technologies.
Of course, I do not mean to imply that U.S. farmers will be immune from 
these trends. As I mentioned earlier, under the industrial patent system it be-
comes illegal for farmers to save seed from patented varieties, or to sell off-
spring from patented livestock, without payment of royalties. This is just one 
example of how the role of farmers in society is changing and will be dramati-
cally affected by emerging biotechnologies. Way back in 1986, Roger Salquist, 
the outspoken president and CEO of Calgene, made an important prediction 
about the impact of commercial biotechnology on agriculture (Salquist 1986). 
He said:
The major thing that’s going to happen in terms of biotech-
nology in agriculture, I believe, the single most startling thing 
is a strategic restructuring of the industry to vertical 
integration...Historically the processors of products from ag-
riculture have purchased them on the commodity markets. 
What’s going to happen with biotechnology is that you’re creating 
proprietary products out of commodities.
Mr. Salquist was right. The biotechnology industry of the future will control 
a product from raw material to the point of consumption. As biotechnology 
firms gain control over every phase of production, processing and marketing—
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from “seed to supermarket” as they say—the role of the farmer is reduced to 
that of a worker who grows crops and livestock under contract. In the devel-
opment of new transgenic crops, for example, the trend is toward the devel-
opment of “use-tailored, identity-preserved” seed varieties that are genetically 
tailored to meet specific needs—not of the farmer, but of the food processor 
(Wheat 1991, Wheat 1992). Under this scenario, the American farmer be-
comes a “renter of germplasm,” rather than an independent, owner/operator. 
The trend is not new, but it will likely accelerate with the commercialization of 
transgenic plants and livestock. Agricultural economists such as Michael 
Boehlje (1992) predict that up to 40 percent of U.S. farmers will be growing 
“value-added” crops under contract by the year 2000.
ENVIRONMENTAL CONCERNS
Well, what about environmental stewardship? Will the biotechnology indus-
try deliver on its promise to bring us a more environmentally friendly agricul-
ture? Will new biotechnologies promote sustainable agriculture? These are 
issues that have been the subject of intense debate over the past years.
I am not an expert on the environmental impacts of biotechnology, nor is 
it the area I focus on day to day, but we do have concerns about the potential 
ecological risks involved with genetic engineering. RAFI and many other farm 
advocacy organizations continue to question whether or not the biotechnol-
ogy industry will deliver on its promises to bring us a more sustainable system 
of agriculture. Several years ago, I coauthored a report entitled Bitter Harvest: 
Herbicide Tolerant Crops and the Threat to Sustainable Agriculture (Goldburg et 
al. 1990). This report is four years old, but our basic analysis remains the same. 
The bottom line is that agrichemical corporations are not developing herbi-
cide-tolerant varieties because they want to clean up the environment, but 
because they are interested in selling more herbicides. Rather than moving us 
away from chemical dependence in agriculture, herbicide-resistant crops will 
entrench our reliance on toxic chemical weedkillers.
The biotechnology industry assures us that herbicide-tolerant crops will 
be engineered to resist only newer, less toxic herbicides. We reject that claim 
(Shand 1993b). The U.S. Department of Agriculture’s (USDA) recent ap-
proval of Calgene’s bromoxynil-resistant cotton is a case in point.9 Bromo- 
xynil is a known cause of birth defects in laboratory animals and is highly toxic 
to both fish and wildlife. With commercial sale of bromoxynil-resistant cot-
ton, farmers can use a post-emergent herbicide on cotton for the first time. 
Here we see biotechnology being used to create new uses for a dangerous her-
bicide. It is a far cry from environmentally benign. Worldwide, herbicide 
tolerance is the trait most commonly tested in transgenic crops. In the U.S. 
approximately 40 percent of the field test applications for transgenic plants 
have been for herbicide tolerance.
9 USDA/APHIS approved Calgene’s petition for its bromoxynil-resistant cotton 
varieties for nonregulated status under USDA regulations on February 15, 1994.
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Overall, we think it is important to acknowledge that genetic engineering 
of plants and microorganisms is new and still untested on a large scale. With 
genetic engineering the species barrier has been broken—allowing scientists 
to fashion new organisms that are not found in nature or in traditionally bred 
organisms. At this point, we have very limited experience with the use and be-
havior of novel transgenic plants, animals and microorganisms.
Of course, there is a great deal of important research being done in the 
area of biological insecticides as well as plants genetically engineered for benefi-
cial traits such as insect and virus resistance. But published reports in the past 
few weeks remind me of how little we know, even in those cases where the end 
products are deemed the most socially beneficial and environmentally benign.
In March 1994, for example, scientists at Michigan State University pub-
lished their findings that genetic engineering of plants to resist existing viruses 
may actually stimulate the evolution of new viruses (Greene and Allison 1994). 
While some scientists believe that the risk of creating new and harmful viruses 
is practically nil, the findings of Richard Allison and Ann Greene signal the 
need for further research on genetically engineered virus-resistance in plants. 
After all, approximately 18 percent of the field tests approved by USDA are for 
crops genetically engineered to resist viral diseases. Given the fact that the next 
step is commercialization of these crops, it is prudent to continue research de-
signed to carefully assess the potential risks.
In the May 1993 issue of Bio/Technology magazine, there is an interesting 
editorial by Bernard Dixon, entitled Keeping an Eye on Bacillus thuringiensis 
(Dixon 1993). He begins his commentary by quoting scientists who describe 
Bt as “totally safe” and “nontoxic,” an agent of biological insect control that 
could never pose a threat to human health. But he goes on to describe recent 
reports in the literature that suggest, not conclusively, that “nonpathogenic” 
members of the genus Bacillus can trigger human disease, especially among 
immunocompromised individuals under special circumstances. Based on 
these reports, he suggests that there may be particular grounds for concern 
about the dissemination of B. thuringiensis in areas of Africa with a high preva-
lence of immunosuppressive infections such as childhood measles in, malaria 
and AIDS.
I am not suggesting that we should discontinue research on genetically 
engineered virus-resistant plants or that Bt is harmful to human health. But 
these examples illustrate, I think, how little is known about the possible ad-
verse impacts of introducing genetically engineered plants and microorgan-
isms into the environment—even for those products that are considered the 
most environmentally benign and that clearly offer tremendous benefits for 
agriculture and human health.
In case you have not seen it, I urge you to take a look at the Union of Con-
cerned Scientists’ recent report entitled Perils Amidst the Promise: Ecological 
Risks of Transgenic Crops in a Global Market (Rissler and Mellon 1993). The 
report describes many of the potential ecological risks of transgenic plants and
82
Agricultural Biotechnology &  the Public Good
offers an innovative approach for scientifically assessing two aspects of risk— 
weediness potential and gene flow. The report calls on the U.S. to establish a 
strong federal program to assess and minimize the risks of transgenic crops be-
fore they are commercialized. It does a particularly good job, I think, of de-
scribing the potential threat to centers of crop genetic diversity, both in the 
U.S. and in the developing world.
In light of these risks, I find it particularly disturbing that the Biotech-
nology Industry Organization (BIO), a trade group, is lobbying the Clinton 
Administration to oppose the development of an international biosafety pro-
tocol under the Convention on Biological Diversity (Feldbaum 1994).
CONCLUSION
So, what can be done to address the issues of biopiracy and inequities that may 
result from the development of new biotechnologies that are based on both ge-
netic material and informal innovation of the South (i.e., southern hemisphere)? 
I want to mention a few areas of policy reform that we think are important.
First, the whole notion of intellectual property rights over living materi-
als needs broad societal review. New biotechnologies are being developed at a 
rate far faster than responsible social policies can be devised to guide them, or 
legal systems can evolve to adequately address them. Public debate has lagged 
far behind.
Intellectual property laws are designed to promote innovation, but it is 
clear that the system is out of control in regard to biological products and pro-
cesses. Patents are a legal monopoly given by government in exchange for so-
cietal benefits. I would argue that there is no benefit for society when a single 
company is given exclusive monopoly control over an entire agricultural spe-
cies. Patents are clearly an important marketing tool for biotechnology firms. 
Instead of promoting innovation, however, they may be stifling the free flow 
of information and genetic resources that are so vital to the biotechnology in-
dustry, public researchers and agricultural development worldwide.
We believe that there is an urgent need for the U.S. Congress to reevalu-
ate the role of intellectual property rights as it affects agriculture and the pub-
lic good. Unfortunately, every time in recent history that plant intellectual 
property rights have been amended, it has been to strengthen the rights of 
industry at the expense of farmers and society. The seed industry is lobby-
ing very hard to take away the right of farmers to save and sell proprietary 
seed. And they want the U.S. government to ratify an international conven-
tion that makes it optional for signatories to allow farmers to save seed 
harvested on their own land.10
10 Amendments to the Plant Variety Protection Act, H.R. 2927. Hearing held before 
the House Agriculture Subcommittee on Department Operations and Nutrition. 
May 24, 1994.
Secondly, there are two major shortcomings in the Biodiversity Conven-
tion that need to be addressed by contracting parties in future negotiations:
1. ex situ gene bank material; and 2. farmers’ rights.
The Biodiversity Convention specifically excludes ex situ gene bank ma-
terial collected before the enactment of the Convention. This means that the 
comparatively huge stockpile of agricultural germplasm held in gene banks 
around the world, most of it gathered from tropical and subtropical countries, 
remains outside the agreement. Two-thirds of gene bank collections are con-
trolled by the North (i.e., developed countries in the northern hemisphere). 
Well over four-fifths of livestock and microbial collections are also controlled 
by the North. Because it is usually inventoried and catalogued, this is gener-
ally considered to be material of most immediate value. There is concern that 
germplasm provided freely by the International Agricultural Research Centre 
(IARC) gene banks could become subject to exclusive monopoly, and this, in 
turn, could constrain free exchange of germplasm.
There are some positive developments in this area. Last year, IARCs of 
the Consultative Group on International Agricultural Research (CGIAR) ini-
tiated discussions to place IARC gene banks under the auspices of the Food 
and Agriculture Organization (FAO) of the United Nations (UN). This move 
is intended to guarantee that genebank samples cannot be subjected to exclu-
sive monopoly control under an intellectual property system.
There is also an urgent need for an international funding mechanism, 
under the auspices of the UN, that will recognize, reward and protect the in-
novations of farmers, indigenous peoples and their communities. FAO made 
important progress in this respect by recognizing the principle of farmers’ 
rights. Basically, farmers’ rights recognizes that farmers—past, present and 
future—have contributed greatly to the conservation, use and development 
of plant genetic resources, and that they should be recognized and rewarded 
for those contributions. The principle of farmers’ rights has not been imple-
mented in any meaningful way, but it could be strengthened and imple-
mented as a protocol to the Biodiversity Convention.
Many NGOs, as well as governments, support the creation of a sustained 
international fund, provided for by governments via the standard UN for-
mula and administered through a UN agency governed on the basis of one na-
tion, one vote. Such a fund would not make payments to individual farmers 
or communities, but would direct practical support of specific programs and 
projects, such as training of plant breeders, construction of gene banks, etc., 
to bring about rural development and to conserve and enhance agricultural 
genetic resources.
Ultimately, the goal of such a fund is to enable all countries to share the 
rights and responsibilities of conserving and using biodiversity. The aim is to 
allow even the poorest countries to develop indigenous capacity to exploit their 
own genetic resources and to develop greater self-reliance in food production.
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Similar resolution is needed on the issue of patenting of human genetic 
material. We believe that the contracting parties to the Biodiversity Conven-
tion should respond to the requests of indigenous peoples’ organizations for 
protection from patent claims.
The U.S. government should drop all claims to the human cell lines of 
foreign nationals, and repatriate the materials to the indigenous communities 
or national governments involved.
Finally, international protocols should be developed by the appropriate 
UN bodies for protecting and broadening the rights of human subjects from 
commercial exploitation and patent claims.
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